<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986270</url>
  </required_header>
  <id_info>
    <org_study_id>A160-104</org_study_id>
    <nct_id>NCT01986270</nct_id>
  </id_info>
  <brief_title>Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the efficacy, toleration and safety of eletriptan
      40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects
      with an acute migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">January 1998</completion_date>
  <primary_completion_date type="Actual">January 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Headache response at 1 hour after the first dose for the first attack.</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Headache response was defined as improvement from a severe or moderate headache at baseline to either a mild or absent headache post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-free response at 1 hour after the first dose for the first attack.</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>A pain free response was defined as an improvement from a severe or moderate headache at baseline to an absent headache post-dose.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1141</enrollment>
  <condition>Migraine With or Without Aura</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eletriptan 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eletriptan 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eletriptan 40 mg</intervention_name>
    <description>40mg oral</description>
    <arm_group_label>Eletriptan 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eletriptan 80 mg</intervention_name>
    <description>80mg oral</description>
    <arm_group_label>Eletriptan 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 25 mg</intervention_name>
    <description>25mg oral</description>
    <arm_group_label>Sumatriptan 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 50 mg</intervention_name>
    <description>50mg oral</description>
    <arm_group_label>Sumatriptan 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who expected to suffer at least one acute attack of migraine, with or
             without aura, each 6 weeks (The diagnosis of migraine was to comply with the criteria
             proposed by the International Headache Society (IHS))

          -  Subjects capable of taking medication as outpatients, and recording the effects of
             such medication.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Migraine subjects who also suffered from concomitant frequent (non-migrainous)
             headache, defined as more than six attacks per month on average.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A160-104&amp;StudyName=Comparative%20Study%20of%20Oral%20Eletriptan%20%2840mg%20and%2080mg%29%2C%20Oral%20Sumatriptan%20%2825mg%20and%2050mg%29%20and%20Placebo</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 11, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Eletriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
